{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:57:36Z","timestamp":1781614656619,"version":"3.54.5"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>X-linked lymphoproliferative syndrome type 1 (XLP1) is a rare inborn error of immunity with high mortality rates. Neurological manifestations may be the presenting features and are often fatal; however, their characterization is insufficient, hindering optimal clinical management. The aim of this study is to systematically review the neurological characteristics, outcomes, and survival in XLP1 patients and identify parameters associated with improved prognosis. A PRISMA-guided analysis of PubMed, Web of Science, Scopus, and Embase (up to March 2025) identified studies documenting neurological involvement in genetically verified XLP1 patients. We extracted data on clinical features, neuroimaging findings, therapeutic interventions, and survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 42 genetically verified XLP1 patients with neurological involvement. Central nervous system (CNS) involvement comprised hemophagocytic lymphohistiocytosis (HLH) in 38.1%, vasculitis in 28.6%, and lymphoma in 19% of them. The development of brain vasculitis several months after Burkitt\u2019s lymphoma was a specific presentation. The median age of neurological onset was 5\u2009years. The predominant presenting symptoms were seizures (47.6%), altered consciousness (35.7%), and headaches (21.4%). Neuroimaging frequently revealed abnormalities in the temporal lobe and basal ganglia, often with hemorrhage and edema. Epstein-Barr virus (EBV) was identified in 54.8% of cases, sometimes limited to brain tissue. CSF analysis frequently showed elevated protein and pleocytosis. SH2D1A mutations were diverse, with Arg55 and Trp64 identified as recurrent hot spots. The overall mortality reached 52.4%, with most deaths occurring within five years of neurological onset. Conventional immunosuppressive and cytotoxic treatments were largely ineffective in changing the disease course. In exploratory analysis, hematopoietic stem cell transplantation (HSCT) did not significantly improve survival in the primary dataset, although sensitivity analysis suggested a possible benefit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Neurological involvement in XLP1 exhibits clinical heterogeneity and carries a high mortality rate. Early recognition and timely HSCT may improve survival, demonstrating the importance of vigilant neurological monitoring in affected individuals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-04057-9","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:03:20Z","timestamp":1761044600000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The neurologic face of X-linked lymphoproliferative syndrome type 1: a systematic review"],"prefix":"10.1186","volume":"20","author":[{"given":"Erta","family":"Rajabi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saber","family":"Gharagozlou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kousha","family":"Farhadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moeinadin","family":"Safavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Zamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdolreza","family":"Javadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Rahemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parastoo","family":"Rostami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3397-9716","authenticated-orcid":false,"given":"Nima","family":"Parvaneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"issue":"7913","key":"4057_CR1","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/S0140-6736(75)92004-8","volume":"1","author":"DT Purtilo","year":"1975","unstructured":"Purtilo DT, Cassel CK, Yang JP, Harper R. X-linked recessive progressive combined variable immunodeficiency (Duncan\u2019s disease). Lancet. 1975;1(7913):935\u201340.","journal-title":"Lancet"},{"issue":"7","key":"4057_CR2","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1073\/pnas.84.7.2015","volume":"84","author":"JC Skare","year":"1987","unstructured":"Skare JC, Milunsky A, Byron KS, Sullivan JL. Mapping the X-linked lymphoproliferative syndrome. Proc Natl Acad Sci USA. 1987;84(7):2015\u201318.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6701","key":"4057_CR3","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/26683","volume":"395","author":"J Sayos","year":"1998","unstructured":"Sayos J, Wu C, Morra M, Wang N, Zhang X, Allen D, et al. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature. 1998;395(6701):462\u201369.","journal-title":"Nature"},{"issue":"5","key":"4057_CR4","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/bjh.12422","volume":"162","author":"N Parvaneh","year":"2013","unstructured":"Parvaneh N, Filipovich AH, Borkhardt A. Primary immunodeficiencies predisposed to epstein-barr virus-driven haematological diseases. Br J Haematol. 2013;162(5):573\u201386.","journal-title":"Br J Haematol"},{"issue":"1","key":"4057_CR5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1182\/blood-2010-06-284935","volume":"117","author":"C Booth","year":"2011","unstructured":"Booth C, Gilmour KC, Veys P, Gennery AR, Slatter MA, Chapel H, et al. X-linked lymphoproliferative disease due to SAP\/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease. Blood. 2011;117(1):53\u201362.","journal-title":"Blood"},{"issue":"9","key":"4057_CR6","first-page":"3118","volume":"96","author":"J Sumegi","year":"2000","unstructured":"Sumegi J, Huang D, Lanyi A, Davis JD, Seemayer TA, Maeda A, et al. Correlation of mutations of the SH2D1A gene and Epstein-Barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease. Blood J Am Soc Hematol. 2000;96(9):3118\u201325.","journal-title":"Blood J Am Soc Hematol"},{"key":"4057_CR7","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/B978-1-4377-0774-8.10041-7","volume-title":"Pediatric gastrointestinal and liver disease","author":"C Qualia","year":"2011","unstructured":"Qualia C, Bousvaros A. 41 - gastrointestinal manifestations of primary immunodeficiency. In: Wyllie R, Hyams J, editors. Pediatric gastrointestinal and liver disease. Fourth. Saint Louis: W.B. Saunders; 2011. pp. 435\u201346.e4.","edition":"Fourth"},{"issue":"5","key":"4057_CR8","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s10875-019-00649-w","volume":"39","author":"Z Nademi","year":"2019","unstructured":"Nademi Z, Radwan N, Rao K, Gilmour K, Worth A, Booth C. Different phenotypic presentations of X-Linked lymphoproliferative disease in siblings with identical mutations. J Clin Immunol. 2019;39(5):523\u201326.","journal-title":"J Clin Immunol"},{"key":"4057_CR9","volume-title":"GeneReviews(\u00ae)","author":"L Meyer","year":"1993","unstructured":"Meyer L, Hines M, Zhang K, Nichols KE. X-Linked lymphoproliferative disease. In: Adam M, Feldman J, Mirzaa G, Pagon R, Wallace S, Amemiya A, editors. GeneReviews(\u00ae). Seattle (WA): University of Washington, Seattle. Copyright \u00a9 1993-2024, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.; 1993."},{"key":"4057_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.clim.2018.12.016","volume":"198","author":"B Shadur","year":"2019","unstructured":"Shadur B, Abuzaitoun O, NaserEddin A, Even-Or E, Zaidman I, Stepensky P. Management of XLP-1 and ITK deficiency: the challenges posed by PID with an unpredictable spectrum of disease manifestations. Clin Immunol. 2019;198:39\u201345.","journal-title":"Clin Immunol"},{"issue":"9","key":"4057_CR11","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.braindev.2022.06.004","volume":"44","author":"S Ochiai","year":"2022","unstructured":"Ochiai S, Hayakawa I, Ohashi E, Hamano S, Miyata Y, Sakuma H, et al. Fatal X-linked lymphoproliferative disease type 1-associated limbic encephalitis with positive anti-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antibody. Brain Dev. 2022;44(9):630\u201334.","journal-title":"Brain Dev"},{"key":"4057_CR12","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA, 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"issue":"5","key":"4057_CR13","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1093\/jnen\/nlz018","volume":"78","author":"PR Blackburn","year":"2019","unstructured":"Blackburn PR, Lin WL, Miller DA, Lorenzo-Betancor O, Edwards ES, Zimmermann MT, et al. X-Linked lymphoproliferative syndrome presenting as adult-onset multi-infarct dementia. J Neuropathol Exp Neurol. 2019;78(5):460\u201366.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"2","key":"4057_CR14","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/lary.23433","volume":"123","author":"S Bohne","year":"2013","unstructured":"Bohne S, Kentouche K, Petersen I, Fritzenwanger M, Pletz MW, Lehmberg K, et al. Fulminant epstein-barr virus-associated hemophagocytic lymphohistiocytosis. Laryngoscope. 2013;123(2):362\u201365.","journal-title":"Laryngoscope"},{"key":"4057_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.sleep.2019.03.020","volume":"62","author":"ML B\u00f8rresen","year":"2019","unstructured":"B\u00f8rresen ML, Lundstr\u00f8m KE, Ifversen M, Jennum PJ. Sodium oxybate (xyrem) treatment in severely sleep-deprived child with Epstein-Barr virus encephalitis with lesion of sleep-wake regulation system: a case report. Sleep Med. 2019;62:29\u201331.","journal-title":"Sleep Med"},{"issue":"3","key":"4057_CR16","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/lt.25898","volume":"27","author":"ME Chartier","year":"2021","unstructured":"Chartier ME, Deheragoda M, Gattens M, Dhawan A, Heaton N, Booth C, et al. Successful auxiliary liver transplant followed by hematopoietic stem cell transplantation in X-Linked lymphoproliferative disease type 1. Liver Transpl. 2021;27(3):450\u201355.","journal-title":"Liver Transpl"},{"issue":"1","key":"4057_CR17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1182\/blood.V97.1.95","volume":"97","author":"JP Dutz","year":"2001","unstructured":"Dutz JP, Benoit L, Wang X, Demetrick DJ, Junker A, de Sa D, et al. Lymphocytic vasculitis in X-linked lymphoproliferative disease. Blood. 2001;97(1):95\u2013100.","journal-title":"Blood"},{"issue":"2","key":"4057_CR18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/cei\/uxab019","volume":"207","author":"C Escaron","year":"2022","unstructured":"Escaron C, Ralph E, Bibi S, Visser J, Aric\u00f2 M, Rao K, et al. Diagnosis of HLH: two siblings, two distinct genetic causes. Clin Exp Immunol. 2022;207(2):205\u201307.","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"4057_CR19","doi-asserted-by":"publisher","first-page":"e29314","DOI":"10.1002\/pbc.29314","volume":"69","author":"T Ghosh","year":"2022","unstructured":"Ghosh T, Guerrero-Pena A, Kashyap M, Saad AG, Thorson CM, Pillai AB. Asymptomatic incidental neuroblastoma in a patient with SH2D1A deficiency. Pediatr Blood Cancer. 2022;69(1):e29314.","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"4057_CR20","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/bjh.12454","volume":"163","author":"M Goodyer","year":"2013","unstructured":"Goodyer M, Sargent J, Bond J, McMahon C, Dunne B, Smith O. Allogeneic stem cell transplantation as immunotherapy for X-linked lymphoproliferative disease-associated cerebral T-cell lymphoma. Br J Haematol. 2013;163(1):133\u201335.","journal-title":"Br J Haematol"},{"issue":"7","key":"4057_CR21","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1007\/s10875-015-0194-9","volume":"35","author":"PE Gray","year":"2015","unstructured":"Gray PE, O\u2019Brien TA, Wagle M, Tangye SG, Palendira U, Roscioli T, et al. Cerebral vasculitis in X-linked Lymphoproliferative disease cured by matched unrelated cord blood transplant. J Clin Immunol. 2015;35(7):604\u201309.","journal-title":"J Clin Immunol"},{"issue":"1\u20132","key":"4057_CR22","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jneuroim.2009.10.012","volume":"218","author":"B Hervier","year":"2010","unstructured":"Hervier B, Latour S, Loussouarn D, Rimbert M, De-Saint-Basile G, Picard C, et al. An atypical case of X-linked lymphoproliferative disease revealed as a late cerebral lymphoma. J neuroimmunol. 2010;218(1\u20132):125\u201328.","journal-title":"J neuroimmunol"},{"issue":"6","key":"4057_CR23","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00431-006-0290-1","volume":"166","author":"B H\u00fcgle","year":"2007","unstructured":"H\u00fcgle B, Astigarraga I, Henter J-I, Porwit-MacDonald A, Meindl A, Schuster V. Simultaneous manifestation of fulminant infectious mononucleosis with haemophagocytic syndrome and B-cell lymphoma in X-linked lymphoproliferative disease. Eur J Pediatrics. 2007;166(6):589\u201393.","journal-title":"Eur J Pediatrics"},{"key":"4057_CR24","doi-asserted-by":"crossref","unstructured":"Jiang Y, Firan M, Nandiwada SL, Reyes A, Marsh RA, Vogel TP, et al. The natural history of X-Linked lymphoproliferative disease (XLP1): lessons from a long-term survivor. Case Rep Immunol. 2020, 2020;8841571.","DOI":"10.1155\/2020\/8841571"},{"issue":"6","key":"4057_CR25","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1007\/s10875-021-01032-4","volume":"41","author":"T Karasawa","year":"2021","unstructured":"Karasawa T, Kudo K, Tanita K, Takahashi Y, Kanegane H, Terui K. Epstein-Barr virus-negative granulomatous disease due to SAP deficiency. J Clin Immunol. 2021;41(6):1372\u201375.","journal-title":"J Clin Immunol"},{"issue":"1","key":"4057_CR26","first-page":"3705376","volume":"2018","author":"MM Korah-Sedgwick","year":"2018","unstructured":"Korah-Sedgwick MM, Wall LA. EBV infection in XLP1 manifested solely by behavioral aggression and effective treatment using rituximab. Case Rep Immunol. 2018;2018(1):3705376.","journal-title":"Case Rep Immunol"},{"issue":"8","key":"4057_CR27","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1097\/MPH.0000000000001424","volume":"41","author":"N Kusano","year":"2019","unstructured":"Kusano N, Sakata N, Sugimoto K, Miyazawa T, Ueda S, Okano M, et al. An 18-year-old male with X-linked lymphoproliferative syndrome type 1 who developed primary central nervous system lymphoma 6 months after primary epstein-barr virus infection. J Pediatr Hematol Oncol. 2019;41(8):e538\u201341.","journal-title":"J Pediatr Hematol Oncol"},{"key":"4057_CR28","doi-asserted-by":"publisher","first-page":"- 2022","DOI":"10.3389\/fped.2022.812590","volume":"10","author":"WK Kwon","year":"2022","unstructured":"Kwon WK, Kim JA, Park J-H, Kim DR, Park SE, Kim YJ, et al. Case report: Novel splicing variant in SH2D1A in a patient with X-Linked lymphoproliferative syndrome type 1. Front pediatr. 2022;10:2022.","journal-title":"Front pediatr"},{"key":"4057_CR29","doi-asserted-by":"publisher","first-page":"1381472","DOI":"10.3389\/fimmu.2024.1381472","volume":"15","author":"B Li","year":"2024","unstructured":"Li B, Chen W, Cai X, Hai Y, Pang Q, Xiang W, et al. Case report: Non-EBV associated cerebral vasculitis and cerebral hemorrhage in X-linked lymphoproliferative disease. Front Immunol. 2024;15:1381472.","journal-title":"Front Immunol"},{"issue":"2","key":"4057_CR30","doi-asserted-by":"publisher","first-page":"e523","DOI":"10.1542\/peds.2011-0870","volume":"129","author":"E Mejstr\u00edkov\u00e1","year":"2012","unstructured":"Mejstr\u00edkov\u00e1 E, Janda A, Hrus\u00e1k O, Buckov\u00e1 H, Vlckov\u00e1 M, Hanc\u00e1rov\u00e1 M, et al. Skin lesions in a boy with X-linked lymphoproliferative disorder: comparison of 5 SH2D1A deletion cases. Pediatrics. 2012;129(2):e523\u20138.","journal-title":"Pediatrics"},{"issue":"9","key":"4057_CR31","doi-asserted-by":"publisher","first-page":"e 7949","DOI":"10.1002\/ccr3.7949","volume":"11","author":"T Mukai","year":"2023","unstructured":"Mukai T, Waki K. X-linked lymphoproliferative syndrome associated with Epstein-Barr virus encephalitis and lymphoproliferative disorder. Clin Case Rep. 2023;11(9):e 7949.","journal-title":"Clin Case Rep"},{"issue":"4","key":"4057_CR32","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1097\/IAE.0b013e318206cd67","volume":"31","author":"S Nallasamy","year":"2011","unstructured":"Nallasamy S, Eagle RC Jr., Rorke-Adams L, Nichols KE, Brucker AJ. Eye findings in X-linked lymphoproliferative disorder. Retina. 2011;31(4):790\u201397.","journal-title":"Retina"},{"issue":"2","key":"4057_CR33","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1097\/INF.0000000000002154","volume":"38","author":"JF Neves","year":"2019","unstructured":"Neves JF, Raga LT, Chiang SCC, Tesi B, Vieira JP, Cordeiro AI, et al. Fatal central nervous system lymphocytic vasculitis after treatment for burkitt lymphoma in a patient with a SH2D1A mutation. Pediatr Infect Dis J. 2019;38(2):e29\u201331.","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"4057_CR34","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1128\/CVI.00002-13","volume":"20","author":"C Ortega","year":"2013","unstructured":"Ortega C, Est\u00e9vez Orlando A, Fern\u00e1ndez S, Aguado R, Rumbao Jos\u00e9 M, Gonzalez T, et al. Interleukin-21 overexpression dominates T cell response to Epstein-Barr virus in a fatal case of X-Linked lymphoproliferative syndrome type 1. Clin Vaccine Immunol. 2013;20(5):765\u201371.","journal-title":"Clin Vaccine Immunol"},{"issue":"4","key":"4057_CR35","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1177\/13524585211053565","volume":"28","author":"A Parida","year":"2021","unstructured":"Parida A, Abdel-Mannan O, Mankad K, Foster K, Ramdas S, Ram D, et al. Isolated central nervous system familial hemophagocytic lymphohistiocytosis (fHLH) presenting as a mimic of demyelination in children. Multiple Scler J. 2021;28(4):669\u201375.","journal-title":"Multiple Scler J"},{"issue":"2","key":"4057_CR36","doi-asserted-by":"publisher","first-page":"171","DOI":"10.4103\/0976-3147.131669","volume":"5","author":"S Sankararaman","year":"2014","unstructured":"Sankararaman S, Riel-Romero RM, Jeroudi M, Gonzalez-Toledo E. Epstein-Barr virus induced hemophagocytic lymphohistiocytosis in X-linked lymphoproliferative disease. J Neurosci Rural Pract. 2014;5(2):171\u201374.","journal-title":"J Neurosci Rural Pract"},{"issue":"1","key":"4057_CR37","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12887-019-1444-4","volume":"19","author":"J Sheth","year":"2019","unstructured":"Sheth J, Patel A, Shah R, Bhavsar R, Trivedi S, Sheth F. Rare cause of hemophagocytic lymphohistiocytosis due to mutation in PRF1 and SH2D1A genes in two children - a case report with a review. BMC Pediatrics. 2019;19(1):73.","journal-title":"BMC Pediatrics"},{"issue":"6","key":"4057_CR38","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1055\/s-0032-1323836","volume":"224","author":"D Sperl","year":"2012","unstructured":"Sperl D, Benesch M, Urban C, Lackner H, Sovinz P, Speicher MR, et al. Fatal EBV infection and variable clinical manifestations in an XLP-1 pedigree - rapid diagnosis of primary immunodeficiencies may save lives. Klin PadiAtr. 2012;224(6):386\u201389.","journal-title":"Klin PadiAtr"},{"key":"4057_CR39","doi-asserted-by":"crossref","unstructured":"Steininger J, Rossmanith R, Geier CB, Leiss-Piller A, Thonhauser L, Weiss S, et al. Case report: meningoencephalitis with thrombotic occlusive vasculopathy in a Young EBV-Na\u00efve Boy is associated with a novel SH2D1A mutation. Front Immunol. 2021;12.","DOI":"10.3389\/fimmu.2021.747738"},{"issue":"6","key":"4057_CR40","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1002\/pbc.22185","volume":"53","author":"KR Talaat","year":"2009","unstructured":"Talaat KR, Rothman JA, Cohen JI, Santi M, Choi JK, Guzman M, et al. Lymphocytic vasculitis involving the central nervous system occurs in patients with X-linked lymphoproliferative disease in the absence of Epstein-Barr virus infection. Pediatr Blood Cancer. 2009;53(6):1120\u201323.","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"4057_CR41","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/pbc.21790","volume":"52","author":"H Trottestam","year":"2009","unstructured":"Trottestam H, Beutel K, Meeths M, Carlsen N, Heilmann C, Pa\u0161i\u0107 S, et al. Treatment of the X-linked lymphoproliferative, Griscelli and Ch\u00e9diak-Higashi syndromes by HLH directed therapy. Pediatr Blood Cancer. 2009;52(2):268\u201372.","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"4057_CR42","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1212\/01.wnl.0000265597.56202.6c","volume":"69","author":"H Verhelst","year":"2007","unstructured":"Verhelst H, Van Coster R, Bockaert N, Laureys G, Latour S, Fischer A, et al. Limbic encephalitis as presentation of a sap deficiency. Neurology. 2007;69(2):218\u201319.","journal-title":"Neurology"},{"issue":"3","key":"4057_CR43","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ejpn.2013.11.012","volume":"18","author":"M Voeten","year":"2014","unstructured":"Voeten M, Maes P, Wojciechowski M, Vandenbossche L, Meyts I, Ceulemans B. Extremely elevated cerebrospinal fluid protein levels in a child with neurologic symptoms: beware of haemophagocytic lymphohistiocytosis. Eur J Paediatr Neurol. 2014;18(3):427\u201329.","journal-title":"Eur J Paediatr Neurol"},{"issue":"4","key":"4057_CR44","first-page":"884","volume":"27","author":"JK Weeks","year":"2006","unstructured":"Weeks JK, Helton KJ, Conley ME, Onciu M, Khan RB. Diffuse CNS vasculopathy with chronic Epstein-Barr virus infection in X-linked lymphoproliferative disease. AJNR Am J neuroradiol. 2006;27(4):884\u201386.","journal-title":"AJNR Am J neuroradiol"},{"issue":"3","key":"4057_CR45","first-page":"e 1873","volume":"10","author":"L Wu","year":"2022","unstructured":"Wu L, Yang F, Wang J, Yang F, Liang M, Yang H. Exon skipping caused by a complex structural variation in SH2D1A resulted in X-linked lymphoproliferative syndrome type 1. Mol Genet Evidence Med. 2022;10(3):e 1873.","journal-title":"Mol Genet Evidence Med"},{"issue":"12","key":"4057_CR46","doi-asserted-by":"publisher","first-page":"673","DOI":"10.5732\/cjc.012.10238","volume":"32","author":"J Zhu","year":"2013","unstructured":"Zhu J, Zhang Y, Zhen ZJ, Chen Y, Wang J, Cai RQ, et al. Lymphoma and cerebral vasculitis in association with X-linked lymphoproliferative disease. Chin J Cancer. 2013;32(12):673\u201377.","journal-title":"Chin J Cancer"},{"issue":"2","key":"4057_CR47","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/ajh.20261","volume":"78","author":"H Kanegane","year":"2005","unstructured":"Kanegane H, Ito Y, Ohshima K, Shichijo T, Tomimasu K, Nomura K, et al. X-linked lymphoproliferative syndrome presenting with systemic lymphocytic vasculitis. Am J Hematol. 2005;78(2):130\u201333.","journal-title":"Am J Hematol"},{"issue":"4","key":"4057_CR48","first-page":"669","volume":"96","author":"JK Hamilton","year":"1980","unstructured":"Hamilton JK, Paquin LA, Sullivan JL, Maurer HS, Cruzi FG, Provisor AJ, et al. X-Linked lymphoproliferative syndrome registry report. J Sport Hist Of Pediatrics. 1980;96(4):669\u201373.","journal-title":"J Sport Hist Of Pediatrics"},{"issue":"5","key":"4057_CR49","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/j.1399-3038.2012.01282.x","volume":"23","author":"H Kanegane","year":"2012","unstructured":"Kanegane H, Yang X, Zhao M, Yamato K, Inoue M, Hamamoto K, et al. Clinical features and outcome of X-linked lymphoproliferative syndrome type 1 (SAP deficiency) in Japan identified by the combination of flow cytometric assay and genetic analysis. Pediatr Allergy Immunol. 2012;23(5):488\u201393.","journal-title":"Pediatr Allergy Immunol"},{"issue":"6","key":"4057_CR50","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/j.jaci.2014.04.043","volume":"134","author":"R Meazza","year":"2014","unstructured":"Meazza R, Tuberosa C, Cetica V, Falco M, Parolini S, Grieve S, et al. Diagnosing XLP1 in patients with hemophagocytic lymphohistiocytosis. J Allergy Clin Immunol. 2014;134(6):1381\u20137.e7.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"4057_CR51","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00431-019-03512-7","volume":"179","author":"T Xu","year":"2020","unstructured":"Xu T, Zhao Q, Li W, Chen X, Xue X, Chen Z, et al. X-linked lymphoproliferative syndrome in mainland China: Review of clinical, genetic, and immunological characteristic. Eur J PediAtr. 2020;179(2):327\u201338.","journal-title":"Eur J PediAtr"},{"issue":"5","key":"4057_CR52","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2010-07-298372","volume":"117","author":"J Pachlopnik Schmid","year":"2011","unstructured":"Pachlopnik Schmid J, Canioni D, Moshous D, Touzot F, Mahlaoui N, Hauck F, et al. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1\/SAP deficiency) versus type 2 (XLP-2\/XIAP deficiency). Blood. 2011;117(5):1522\u201329.","journal-title":"Blood"},{"issue":"4","key":"4057_CR53","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1203\/00006450-199510000-00001","volume":"38","author":"TA Seemayer","year":"1995","unstructured":"Seemayer TA, Gross TG, Egeler RM, Pirruccello SJ, Davis JR, Kelly CM, et al. X-linked lymphoproliferative disease: twenty-five years after the discovery. Pediatr Res. 1995;38(4):471\u201378.","journal-title":"Pediatr Res"},{"issue":"10","key":"4057_CR54","doi-asserted-by":"publisher","first-page":"e847","DOI":"10.1212\/WNL.0000000000005062","volume":"90","author":"C Salvarani","year":"2018","unstructured":"Salvarani C, Brown RD Jr, Christianson TJH, Huston J 3rd, Ansell SM, Giannini C, et al. Primary central nervous system vasculitis associated with lymphoma. Neurology. 2018;90(10):e847\u201355.","journal-title":"Neurology"},{"key":"4057_CR55","doi-asserted-by":"crossref","unstructured":"Blincoe A, Heeg M, Campbell PK, Hines M, Khojah A, Klein-Gitelman M, et al. Neuroinflammatory disease as an isolated manifestation of Hemophagocytic Lymphohistiocytosis. J Clin Immunol. 2020;40(6):901\u201316.","DOI":"10.1007\/s10875-020-00814-6"},{"key":"4057_CR56","doi-asserted-by":"crossref","unstructured":"Lindahl H, Bryceson YT. Neuroinflammation associated with inborn errors of immunity. Front Immunol. 2021;12:827815.","DOI":"10.3389\/fimmu.2021.827815"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04057-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-04057-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04057-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:19:38Z","timestamp":1781612378000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-025-04057-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4057"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-04057-9","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"22 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Children\u2019s Medical Center Institutional Ethics Committee, affiliated with Tehran University of Medical Sciences. Written informed consent for participation in the study was obtained from the patient\u2019s family. Our study adhered to the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication of the patient\u2019s clinical data was obtained from the family.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"528"}}